Neurocrine Biosciences Inc (NBIX) Dividend History

Company News

• Nxera Pharma to Receive US$15 Million from Neurocrine Biosciences Following Dosing of First Patient in Phase 3 Trial of NBI-1117568

  Nxera Pharma announced that its partner Neurocrine Biosciences has dosed the first patient in a Phase 3 trial of NBI-1117568 for schizophrenia, triggering a $15 million payment to Nxera.

  GlobeNewswire Inc.
• Nxera Pharma Notes Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025

  Nxera Pharma notes that Neurocrine Biosciences presented positive data from a Phase 2 study of NBI-1117568 in adults with schizophrenia.

  GlobeNewswire Inc.
• Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2025

  Nxera Pharma, a Japanese biopharma company, reported its Q1 2025 results, highlighting progress in its partnered and in-house drug development programs, including the initiation of Phase 3 trials for a schizophrenia treatment. The company's financial performance showed improved profitability compared to the previous year.

  GlobeNewswire Inc.

  Featured Companies: VTRS
• Sodium Channel Blockers Clinical Trial Pipeline Accelerates as 20+ Pharma Companies Rigorously Developing Drugs for Market Entry | DelveInsight

  The sodium channel blocker market is expanding due to the increasing prevalence of neuropathic pain and the rising incidence of cardiac arrhythmias. Over 20 pharmaceutical companies are actively developing 25+ pipeline sodium channel blockers, with promising drugs like Cenobamate, VX-548, and Vormatrigine in different clinical trial phases.

  GlobeNewswire Inc.

  Featured Companies: DWTX PRAX VRTX
• Acetylcholine Receptor Antagonists Clinical Trial Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

  The article discusses the robust pipeline of acetylcholine receptor antagonists, with over 30 key pharmaceutical companies actively working on developing new therapies in this segment. The advancements in drug development, including new formulations and targeted therapies, are enhancing the efficacy and safety of these drugs, leading to increased market growth.

  GlobeNewswire Inc.

  Featured Companies: AXSM BMY